TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16798862
Drug: Atraumatic Restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic Restorative Treatment (ART) with high-viscosity glass ionomer
Study: 10974963
Drug: Active medication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medication review by a pharmacist
Study: 1323576
Drug: 10(6) TCID50
Normalized name: adenovirus type 4 vaccine live
DrugBank: Human adenovirus e serotype 4 strain cl-68578 antigen (DB14409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10(6) TCID50 of CP18 PIV‐3 vaccine administered intranasally to seropositive older children (41 to 124 months)
Study: 1323576
Drug: 10(5) TCID50
Normalized name: adenovirus type 4 vaccine live
DrugBank: Human adenovirus e serotype 4 strain cl-68578 antigen (DB14409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10(5) TCID50 of CP18 PIV‐3 vaccine administered intranasally to seropositive young children
Study: 1323576
Drug: 10(6) TCID50
Normalized name: adenovirus type 4 vaccine live
DrugBank: Human adenovirus e serotype 4 strain cl-68578 antigen (DB14409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10(6) TCID50 of CP18 PIV‐3 vaccine administered intranasally to seropositive young children
Study: 1323576
Drug: 10(6) TCID50
Normalized name: adenovirus type 4 vaccine live
DrugBank: Human adenovirus e serotype 4 strain cl-68578 antigen (DB14409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10(6) TCID50 of CP18 PIV‐3 vaccine administered intranasally to seronegative young children
Study: 1323576
Drug: CP18 PIV‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP18 PIV‐3 vaccine in seronegative young children
Study: 1323576
Drug: Vaccine virus
Normalized name: Rubella virus vaccine
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine virus spread from a vaccinated child to a sibling control
Study: 31168922
Drug: Intensive lifestyle
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive lifestyle intervention (5-6 weekly aerobic and combined aerobic and strength training sessions, 30-60 minutes, individual dietary plans aiming for BMI ≤25 kg/m2)
Study: 31168922
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (standardized, blinded, target-driven medical therapy during the initial 12 months)
Study: 30170399
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine fumigation 'Bone-healing Powder'
Study: 27210235
Drug: BoNT/A injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT/A injection (100 units)
Study: 25219601
Drug: Baicalein (100-2800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baicalein (100-2800 mg)
Study: 22727067
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of nateglinide (60 mg)
Study: 22727067
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of nateglinide (60 mg)
Study: 19655157
Drug: Ethinylestradiol +
Normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinylestradiol + cyproterone acetate (2 mg, EE/CA)
Study: 19655157
Drug: Ethinylestradiol +
Normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinylestradiol + cyproterone acetate (2 mg, EE/CA) with spironolactone (Sp)
Study: 17585086
Drug: Hydrocortisone (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (1200 mg/d for 10 days, tapered thereafter)
Study: 10549990
Drug: GHB (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB (50 mg/kg body weight for 10 days)
Study: 10549990
Drug: Diazepam (0.5-0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.5-0.75 mg/kg body weight for 6 days, tapering the dose 25% daily until day 10)
Study: 7634674
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for avulsion fractures (no immobilization)
Study: 7634674
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for shaft/neck fractures (plaster casts with weight bearing as tolerated)
Study: 7634674
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for true Jones' fractures (8 weeks nonweight bearing followed by weight bearing as tolerated in a cast)
Study: 7634674
Drug: Surgical fixation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical fixation for conservative treatment failure
Study: 2179764
Drug: 5 X
Normalized name: PAD,ABDOMINAL 5 X 9 STERILE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 X 10(6) IU IFN subcutaneously daily for 6 months
Study: 30972062
Drug: Myeloid-derived cells
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myeloid-derived cells targeted treatments
Study: 21261786
Drug: Oral and/or
Normalized name: Chloral and/or chloral derivative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and/or parenteral rehydration solutions
Study: 19479626
Drug: Quercetin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (250 mg)
Study: 15319599
Drug: 99mTc nanocolloid
Normalized name: 99mTc medronate
DrugBank: Technetium Tc-99m medronate (DB09138)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc nanocolloid (99mTc‐NC) (10 MBq) and 111In‐HIG (2 MBq) as a mixture (0.2 ml)
Study: 15319599
Drug: 99mTc‐HIG (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc‐HIG (10 MBq) and 111In‐HIG (2 MBq) as a mixture (0.2 ml)
Study: 15319599
Drug: 99mTc‐HIG (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc‐HIG (10 MBq) and 111In‐HIG (2 MBq) separately (both 0.2 ml)
Study: 9611088
Drug: Tryptophan depletion
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tryptophan depletion (TD) challenge with 43 g of an amino acid mixture containing five large neutral amino acids
Study: 9611088
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received the same amino acid mixture with 2.3 g tryptophan added
Study: 9611088
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of platelet serotonin-receptor function and plasma prolactin levels
Study: 30999382
Drug: Combined massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined massage therapy and phototherapy
Study: 28343774
Drug: 60μg recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60μg recombinant hepatitis B vaccine
Study: 28343774
Drug: 20μg recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20μg recombinant hepatitis B vaccine
Study: 28343774
Drug: Both 20μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both 20μg and 60μg vaccine groups
Study: 26521577
Drug: Conventional rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rehabilitation therapy (intermittent catheterization and bladder function training)
Study: 22083887
Drug: Routine 3,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine 3,000 mL LCAP
Study: 15073160
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) at a dosage of 300-500 mg/kg (most commonly 400 mg/kg)
Study: 11319684
Drug: HPV-11 L1
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-11 L1 VLP vaccine
Study: 2446080
Drug: Intravenous ketanserin
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketanserin (0.15 mg/kg)
Study: 27466602
Drug: Soy-dairy protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy-dairy protein blend (PB) supplementation (22 g daily)
Study: 27466602
Drug: Combined PB
Normalized name: PB-722
DrugBank: PB-722 (DB18447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined PB and WP treatments
Study: 28346813
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (PB, WP, MDP)
Study: 18547727
Drug: Escitalopram 20mg
Normalized name: Escitalopram 20mg Oral tablet
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram 20mg once daily
Study: 15647413
Drug: Hibiscus sabdariffa
Normalized name: HIBISCUS SABDARIFFA CALYX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hibiscus sabdariffa L. extract (150 mL yielding 62.6 mg of cyanidin‐3‐sambubioside, 81.6 mg of delphinidin‐3‐sambubioside, and 147.4 mg of total anthocyanins)
Study: 15647413
Drug: Hibiscus sabdariffa
Normalized name: HIBISCUS SABDARIFFA CALYX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hibiscus sabdariffa L. extract
Study: 10862852
Drug: Prostaglandin E(2)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E(2) gel (0.5 microg every 6 hours for two doses followed by oxytocin if indicated)
Study: 9932568
Drug: Extra-amniotic saline
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-amniotic saline infusion
Study: 9089422
Drug: AZT-P-ddI (IVX-E-59)
Normalized name: E.P.O.
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZT-P-ddI (IVX-E-59) intravenous administration (50 mg and 100 mg)
Study: 9089422
Drug: AZT-P-ddI (IVX-E-59)
Normalized name: E.P.O.
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZT-P-ddI (IVX-E-59) oral administration (100 mg and 200 mg)
Study: 9089422
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg oral dose of AZT-P-ddI
Study: 9089422
Drug: AZT-P-ddI (IVX-E-59)
Normalized name: E.P.O.
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZT-P-ddI (IVX-E-59) oral administration
Study: 9089422
Drug: AZT-P-ddI (IVX-E-59)
Normalized name: E.P.O.
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZT-P-ddI (IVX-E-59) oral and intravenous administration
Study: 8478959
Drug: 0.5 g/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/m2 DFMO every day (step 3)
Study: 8478959
Drug: 0.125, 0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125, 0.25, 0.5, or 0.75 g/m2 DFMO four times a day (step 1)
Study: 8478959
Drug: 0.125 or
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 or 0.25 g/m2 four times a day or 0.5 or 1.0 g/m2 every day (step 2)
Study: 8478959
Drug: 0.5 g/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/m2 DFMO every day
Study: 27128958
Drug: Minocycline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (50 mg twice per day)
Study: 24452704
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A injection at the proximal 2/10 and 3/10 of calf length
Study: 24452704
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A injection at and below the midbelly of the muscle (Control)
Study: 22157067
Drug: MRI-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI-guided treatment decision (group 2)
Study: 22157067
Drug: MRI-blinded treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI-blinded treatment decision (group 1)
Study: 22157067
Drug: Different injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different injection than proposed by independent physician (group 1)
Study: 22157067
Drug: Injection correlated
Normalized name: TUBING,CORRUGATED FLEX HUDSON #1680
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection correlated with imaging (group 1)
Study: 16183781
Drug: Propiverine 15
Normalized name: propiverine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine 15 mg twice daily for 7 days
Study: 11291023
Drug: Psychopharmacologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychopharmacologic treatment for hypersexuality
Study: 11291023
Drug: Clinical algorithm
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical algorithm for treatment
Study: 31711417
Drug: Ephedrine 20
Normalized name: DM 10/PSEUDOEPHEDRINE 20MG/5ML LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 20 mg (E group)
Study: 31711417
Drug: Phenylephrine 250
Normalized name: acetaminophen-phenylephrine 250 mg-5 mg oral tablet, effervescent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine 250 mcg (P group)
Study: 16648333
Drug: Video-feedback interactional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video-feedback interactional treatment
Study: 10926346
Drug: Salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone propionate combination product (SFC) 50/250 microg twice daily
Study: 1526015
Drug: UK 79300
Normalized name: UK-390957
DrugBank: UK-390957 (DB11719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK 79300 (100 mg, twice daily)
Study: 1526015
Drug: UK 79300
Normalized name: UK-390957
DrugBank: UK-390957 (DB11719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK 79300 (25 mg)
Study: 2868640
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg tablet of Ea-0643 (group-A)
Study: 2868640
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg tablet of Ea-0643 (group-B)
Study: 2868640
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet (group-C)
Study: 27978537
Drug: Anti-rabies vaccine
Normalized name: rabies virus vaccine flury-lep strain Injection [RabAvert]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-rabies vaccine (control group)
Study: 22976514
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy applied with output power of 100 mW in continuous mode with sweeping motion.
Study: 16644631
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg muraglitazar
Study: 10657761
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin (CAP) 0.05% liniment applied 3 times daily for 5 days
Study: 10657761
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin (CAP)
Study: 31032742
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser treatment (MicroLaserPeel™ and ProFractional™)
Study: 22426952
Drug: Morning teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Morning teriparatide (20 μg daily)
Study: 22426952
Drug: Evening teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Evening teriparatide (20 μg daily)
Study: 20722561
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg/day) for 3 months
Study: 20722561
Drug: Stable dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable dose of ACEIs and/or ARBs
Study: 1333741
Drug: Lysine-aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine-aspirin
Study: 30573499
Drug: Topical brimonidine
Normalized name: brimonidine Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical brimonidine tartrate 0.15% administered 20 min prior to injection
Study: 29136445
Drug: 250 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 μg peanut patch
Study: 29136445
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg peanut patch
Study: 29136445
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg peanut patch
Study: 29136445
Drug: 250 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 μg peanut patch (6-11 years)
Study: 29136445
Drug: 250 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 μg peanut patch (adolescents/adults)
Study: 15027519
Drug: Lactic acid
Normalized name: Lactic Acid
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactic acid 12% and pramoxine hydrochloride 1% cream applied twice daily for 7 days
Study: 11309549
Drug: Lotrafiban (5-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotrafiban (5-100 mg, twice daily for 12 weeks)
Study: 11309549
Drug: Lotrafiban (exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotrafiban (exposure > 835 ng.h/mL)
Study: 11309549
Drug: Lotrafiban (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotrafiban (lower dose recommendation)
Study: 9203727
Drug: Monoclonal antibody-based
Normalized name: SARS-CoV-2 antibody-based IVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody-based IgM capture ELISA
Study: 3320366
Drug: Flupenthixol 0.5
Normalized name: flupenthixol 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupenthixol 0.5 mg twice daily
Study: 18854910
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate (GA) after mitoxantrone induction (20 mg/d SC)
Study: 18854910
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate (GA) alone (20 mg/d SC)
Study: 12922120
Drug: Diphtheria-tetanus toxoid-acellular
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria-tetanus toxoid-acellular pertussis vaccine
Study: 10342425
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose topical capsaicin (1%)
Study: 8641230
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) at a target dosage of 800 mg/day (400 mg twice daily)
Study: 1523351
Drug: 7 +
Normalized name: menaquinone 7
DrugBank: Menaquinone 7 (DB13075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 + 3 chemotherapy protocol
Study: 1523351
Drug: TADOP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TADOP chemotherapy protocol
Study: 7100823
Drug: Amoxycillin, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin, 50 mg/kg twice daily
Study: 7100823
Drug: Pivampicillin, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivampicillin, 50 mg/kg twice daily
Study: 7100823
Drug: Intramuscular ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular ampicillin
Study: 31070690
Drug: Sorafenib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib plus HAIC (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, fluorouracil bolus 400 mg/m2 on day 1, and fluorouracil infusion 2400 mg/m2 for 46 hours, every 3 weeks)
Study: 28270335
Drug: Primary care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary care treatment as usual (TAU)
Study: 24219891
Drug: High-fructose diet
Normalized name: High Fructose Corn Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fructose diet (150 g per day for 4 weeks)
Study: 24219891
Drug: High-glucose diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-glucose diet (150 g per day for 4 weeks)
Study: 9399010
Drug: Lanepitant 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanepitant 30 mg
Study: 9399010
Drug: Lanepitant 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanepitant 80 mg
Study: 9399010
Drug: Lanepitant 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanepitant 240 mg
Study: 3300274
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (200 mg tid)
Study: 30628519
Drug: sequential naïve
Approvals — FDA: no, EMA: no, PMDA: no
Description: sequential naïve pinhole bone scan (nPBS)
Study: 30628519
Drug: sequential gamma
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sequential gamma correction pinhole bone scan (GCPBS)
Study: 29543506
Drug: Lidcombe Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidcombe Program treatment
Study: 17683491
Drug: Mosapride citrate
Normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride citrate 10 mg 1 hour before CE examination
Study: 16143696
Drug: Bisoprolol (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (target dose 10 mg QD)
Study: 16143696
Drug: Enalapril (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (target dose 10 mg BID)
Study: 2208231
Drug: Nifedipine, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine, 60 mg per day
Study: 2208231
Drug: Diltiazem, 270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem, 270 mg per day
Study: 2208231
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 30 mg nifedipine per day with 180 mg diltiazem per day
Study: 2208231
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 60 mg nifedipine per day with 270 mg diltiazem per day
Study: 7191306
Drug: Indometacin (equimolar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin (equimolar doses, t.i.d. for 10 days)
Study: 7191306
Drug: Acemetacin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acemetacin (single dose)
Study: 7191306
Drug: Indometacin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin (single dose)
Study: 23796764
Drug: Ahmed implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ahmed implant
Study: 22843282
Drug: Tafamidis 20
Normalized name: TAFAMIDIS 20MG TAB UD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafamidis 20 mg QD
Study: 19423108
Drug: Pravastatin (10-20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (10-20mg daily)
Study: 9700992
Drug: Aspirin 990
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 990 mg/day plus dipyridamole 225 mg/day
Study: 18426639
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg folic acid weekly
Study: 7978695
Drug: 27.5 mg
Normalized name: lipase 27.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 27.5 mg folic acid weekly